Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe.
Acceptability
Dapivirine Vaginal Ring
Eastern and Southern Africa
HIV/AIDS
Oral PrEP
Pregnant Persons
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
25 Jul 2024
25 Jul 2024
Historique:
accepted:
18
06
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
25
7
2024
Statut:
aheadofprint
Résumé
Pregnant and lactating persons in sub-Saharan Africa face a heightened risk of HIV acquisition, due to biological and behavioral factors, combined with limited access to prevention and treatment services. Oral pre-exposure prophylaxis (PrEP) and the dapivirine vaginal ring are promising tools for HIV prevention, and the ring's recent approval in multiple African countries represents a significant advancement in expanding access to HIV prevention. In a nested qualitative study within the MTN-042 trial, we explored the acceptability of study products among pregnant persons in the second and early third trimesters. Interviews were conducted privately, using a semi-structured guide with 77 participants, in participants' preferred language. Topics explored included product acceptability (using the theoretical framework of acceptability), user experience, satisfaction, disclosure, community attitudes, and sexual activity during pregnancy. Interview transcripts were analyzed using Dedoose software. We observed positive attitudes among participants towards the study products, which they found generally user-friendly, despite the added complexities of using them during pregnancy. Participants recognized that consistent and correct use would provide protection for both them and their unborn children. Although initial concerns existed, most of these worries dissipated over time, with study staff support and increased product use experience. These findings emphasize the importance of continued surveillance, support, and education to ensure the successful rollout of new HIV prevention measures during pregnancy.
Identifiants
pubmed: 39052199
doi: 10.1007/s10461-024-04421-z
pii: 10.1007/s10461-024-04421-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases
ID : UM1AI068633
Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases
ID : UM1AI068615
Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases
ID : UM1AI106707
Informations de copyright
© 2024. The Author(s).
Références
Drake AL, et al. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med. 2014;11(2):e1001608.
pubmed: 24586123
pmcid: 3934828
Gray RH, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet. 2005;366(9492):1182–8.
pubmed: 16198767
Montgomery ET et al. Reasons for non-adherence to the dapivirine vaginal ring: results of the MTN-032/AHA study AIDS (London, England), 2018.
Birkhead GS, et al. Acquiring human immunodeficiency virus during pregnancy and mother-to-child transmission in New York: 2002–2006. Obstetrics & Gynecology. 2010;115(6):1247–55.
Businge CB, Longo-Mbenza B, Mathews V. Risk factors for incident HIV infection among antenatal mothers in rural Eastern Cape, South Africa. Global Health Action. 2016;9(1):29060.
pubmed: 26800877
Morrison C, et al. Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. JAIDS J Acquir Immune Defic Syndr. 2014;66(2):109–17.
pubmed: 24413042
MacIntyre DA, et al. The vaginal microbiome during pregnancy and the postpartum period in a European population. Sci Rep. 2015;5(1):1–9.
Astawesegn FH, et al. Trends and effects of antiretroviral therapy coverage during pregnancy on mother-to-child transmission of HIV in Sub-saharan Africa. Evidence from panel data analysis. BMC Infect Dis. 2022;22(1):1–13.
The path that ends AIDS: UNAIDS Global AIDS Update 2023. 2023: Geneva: Joint United Nations Programme on HIV/AIDS; 2023. Licence: CC BY-NC-SA 3.0 IGO.
Mayo AJ, et al. Acceptability of the dapivirine vaginal ring for HIV-1 prevention and association with adherence in a phase III trial. AIDS Behav. 2021;25:2430–40.
pubmed: 33713213
pmcid: 8222015
Hodges-Mameletzis I, et al. Pre-exposure prophylaxis for HIV prevention in women: current status and future directions. Drugs. 2019;79:1263–76.
pubmed: 31309457
Organization WH. Policy brief: pre-exposure prophylaxis (PrEP): WHO expands recommendation on oral pre-exposure prophylaxis of HIV infection (PrEP). World Health Organization; 2015.
WHO. In: Organization WH, editor. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Editor: Geneva; 2022.
Organization WH. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection, in WHO News. 2021.
Baeten JM, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–32.
pubmed: 26900902
pmcid: 4993693
Brown ER, et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo‐controlled trial. J Int AIDS Soc. 2020;23(11):e25634.
pubmed: 33206462
pmcid: 7673220
al. M.J.e. HIV sero-conversions among adolescent girl and young female dapivirine vaginal ring (DPV-R) users: early learnings from a demonstration project in Zimbabwe. INTEREST 2023. Maputo; 2023.
Dettinger JC, et al. Perinatal outcomes following maternal pre-exposure prophylaxis (pr EP) use during pregnancy: results from a large pr EP implementation program in Kenya. J Int AIDS Soc. 2019;22(9):e25378.
pubmed: 31498563
pmcid: 6733245
Joseph Davey DL, et al. Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading? J Int AIDS Soc. 2020;23(1):e25426.
pubmed: 31912985
pmcid: 6948023
Bunge K et al. DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy Journal of Acquired Immune Deficiency Syndromes (1999), 2023.
Montgomery ET, et al. Acceptability of the Dapivirine Vaginal Ring and oral Truvada among African users in late-stage of pregnancy. AIDS and Behavior; 2023.
Stoner MC et al. Depression Among Pregnant and Breastfeeding Persons Participating in Two Randomized Trials of the Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis (PrEP) in Malawi, South Africa, Uganda, and Zimbabwe AIDS and Behavior. 2024:1–12.
Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):1–13.
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57.
pubmed: 17872937
Stoner MC et al. Acceptability and Use of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) During Breastfeeding in South Africa, Malawi, Zimbabwe, and Uganda AIDS and Behavior, 2023:1–10.
Roberts ST, et al. Acceptability and preference for 3-month versus 1-month vaginal rings for HIV-1 risk reduction among participants in a phase 1 trial. J Women’s Health. 2022;31(7):1029–39.
Montgomery ET, et al. Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results. Aids. 2018;32(11):1517–25.
pubmed: 29957723
Pintye J, et al. I did not want to give birth to a child who has HIV: experiences using PrEP during pregnancy among HIV-Uninfected Kenyan women in HIV-Serodiscordant couples. J Acquir Immune Defic Syndr. 2017;76(3):259–65.
pubmed: 28777265
pmcid: 5634917
Joseph Davey DL, et al. I had made the decision, and no one was going to stop me—facilitators of PrEP adherence during pregnancy and postpartum in Cape Town, South Africa. AIDS Behav. 2021;25(12):3978–86.
pubmed: 34085132
pmcid: 8174535
Hill LM, et al. Understanding PrEP decision making among pregnant women in Lilongwe, Malawi: a mixed-methods study. J Int AIDS Soc. 2022;25(9):e26007.
pubmed: 36074034
pmcid: 9454413
Ngure K, et al. The role of male partners in women’s participation in research during pregnancy: a case study from the partners demonstration project. Reproductive Health. 2017;14(3):160.
pubmed: 29297375
pmcid: 5751399
Schaal NK et al. Pregnant and breastfeeding women’s attitudes and fears regarding the COVID-19 vaccination. Arch Gynecol Obstet. 2022:1–8.
Alshahrani SM, et al. Pregnant and breastfeeding women’s attitudes and fears regarding COVID-19 vaccination: a nationwide cross-sectional study in Saudi Arabia. International journal of women’s health; 2022:1629–39.
van Der Straten A, et al. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study. J Int AIDS Soc. 2020;23(6):e25536.
pubmed: 32524700
pmcid: 7287313
Young AM et al. Adolescent Girls and Young Women’s Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis AIDS and Behavior. 2023:1–11.
Young AM et al. Male partners’ support and influence on pregnant women’s oral PrEP use and adherence in Malawi. Front Reproductive Health. 2023;5.
Beesham I, et al. Barriers to oral HIV pre-exposure Prophylaxis (PrEP) adherence among pregnant and post-partum women from Cape Town, South Africa. AIDS and Behavior. 2022;26(9):3079–87.
Ridgeway K, et al. Vaginal ring acceptability: a systematic review and meta-analysis of vaginal ring experiences from around the world. Contraception. 2022;106:16–33.
pubmed: 34644609
van der Straten A, et al. First impressions matter: how initial worries influence adherence to the dapivirine vaginal ring. J Acquir Immune Defic Syndr. 2019;81(3):304.
pubmed: 30844995
pmcid: 6571014
Joseph Davey DL, et al. Healthcare provider knowledge and attitudes about pre-exposure prophylaxis (PrEP) in pregnancy in Cape Town, South Africa. AIDS Care. 2020;32(10):1290–4.
pubmed: 32576023